Patent ID: 11883490
Assignee: MIRROR BIOLOGICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of treating a patient with a solid tumor, the method comprising:
inducing the production of endogenous IL-12 in the patient, wherein the endogenous IL-12 is induced by administering a composition comprising activated allogeneic Th1 cells to the patient, wherein the Th1 cells are activated by cross-linking CD3 and CD28;
ablating all or portion of the solid tumor in the patient to generate tissue necrosis along with intratumoral administration of the activated allogeneic Th1 cells;
measuring the level of endogenous IL-12 in the patient; and
readministering the composition until endogenous IL-12 in the plasma of the patient is at least about 5000 pg/ml.